Lupus Research Alliance Funds Novel Approaches to Autoimmune Disease
Event summary
- The Lupus Research Alliance (LRA) awarded six Lupus Innovation Awards, totaling up to $150,000 per year for two years per recipient.
- The awards support projects focused on improving lupus diagnosis and treatment through novel research approaches.
- Recipients include researchers from Icahn School of Medicine at Mount Sinai, Emory University, Johns Hopkins Medicine, Sloan Kettering Institute, University of Michigan, and University of Washington.
- One award supports an early-stage investigator, who is eligible for an additional year of funding.
- Research areas include viral triggers, T cell function, kidney cell behavior, TLR7 signaling, antiphospholipid syndrome, and skin inflammation.
The big picture
The Lupus Research Alliance's continued investment in high-risk, high-reward research underscores the ongoing need for innovative approaches to treating lupus, a disease with limited therapeutic options and a significant unmet need. The focus on early-stage investigators and novel mechanisms reflects a strategic shift towards more targeted and potentially curative therapies, rather than solely managing symptoms. This funding model, with 100% of donations going to research, positions the LRA as a key driver in the lupus research landscape.
What we're watching
- Viral Exposure
- Dr. Asgari’s research into viral triggers could reveal new preventative strategies, but the complexity of viral interactions with the immune system may prove challenging to translate into actionable therapies.
- Clinical Translation
- The success of these projects hinges on the ability to translate findings from mouse models and in-vitro studies into effective treatments for human lupus patients, a historically difficult hurdle.
- Biomarker Validation
- Dr. Fava’s work on urine biomarkers for kidney damage requires rigorous validation to ensure clinical utility and avoid false positives or negatives that could impact patient management.
Related topics